Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges

GuruFocus Research

7 May 2024 at 8:36 am·3-min read

Revenue: Reported Q1 2024 net revenue of $26.0 million from global sales of IMCIVREE, falling short of estimates of $26.90 million.
Net Loss: Q1 2024 net loss widened to $141.37 million, significantly above the estimated net loss of $125.26 million.
Earnings Per Share: EPS for Q1 2024 was -$2.35, underperforming against the estimated EPS of -$2.16.
Research and Development Expenses: R&D expenses dramatically increased to $128.67 million in Q1 2024 from $37.95 million in the previous year.
Operational Funding: Secured $150 million in convertible preferred stock financing, extending operational funding into 2026.
Upcoming Regulatory Submissions: On track to submit a supplementary New Drug Application (sNDA) for IMCIVREE for pediatric use in Q2 2024.
Financial Guidance: Anticipates Non-GAAP Operating Expenses between $250 million and $270 million for the full year 2024.

Warning! GuruFocus has detected 3 Warning Signs with RYTM.

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) released its 8-K filing on May 7, 2024, disclosing its financial results for the first quarter ended March 31, 2024. The company reported a net revenue of $26.0 million from global sales of IMCIVREE (setmelanotide), aligning closely with the analyst's estimated revenue of $26.90 million for the quarter.

Company Profile

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with rare neuroendocrine diseases through the development and commercialization of innovative peptide therapeutics. Its flagship product, setmelanotide (IMCIVREE), targets the melanocortin-4 receptor (MC4R) pathway to treat rare genetic disorders of obesity. The company primarily operates in the United States, Germany, and other regions, with the bulk of its revenue generated domestically.

Financial Performance and Strategic Milestones

The first quarter of 2024 marked a significant period for Rhythm Pharmaceuticals with a reported net loss of $141.4 million, or a loss of $2.35 per share, which was a notable increase from the loss of $52.2 million, or $0.92 per share, in the same quarter the previous year. This loss exceeded the analyst's estimated loss per share of $2.16. The increase in net loss was primarily due to escalated research and development expenses, which totaled $128.7 million compared to $37.9 million in Q1 2023, reflecting the company's continued investment in its clinical programs.

Strategically, Rhythm Pharmaceuticals remains focused on expanding the global reach and therapeutic potential of setmelanotide. The company is on track to submit a supplementary New Drug Application (sNDA) to the FDA for treating pediatric patients aged 2 to 6 years under existing indications. Additionally, the ongoing global Phase 3 trial of setmelanotide in hypothalamic obesity is progressing as planned, with topline data expected in the first half of 2025.

Operational and Financial Outlook

Rhythm Pharmaceuticals secured $150 million in convertible preferred stock financing, which, along with its current financial resources, is expected to fund operations into 2026. For the full year 2024, the company anticipates Non-GAAP Operating Expenses to be between $250 million and $270 million. This financial guidance reflects the company's strategic focus on advancing its clinical development programs and expanding the commercial footprint of IMCIVREE.

Analysis of Financial Statements

The company's balance sheet shows a decrease in total assets from $332.7 million at the end of 2023 to $258.7 million as of March 31, 2024. This decline is primarily attributed to a reduction in short-term investments and a slight decrease in cash and cash equivalents. The increase in total liabilities from $163.0 million to $197.1 million is driven by long-term deferred royalty obligations and other long-term liabilities.

In conclusion, while Rhythm Pharmaceuticals faces significant financial losses and challenges, its strategic initiatives and robust pipeline of clinical programs highlight its commitment to addressing unmet needs in rare genetic disorders of obesity. The company's ability to maintain operational funding into 2026 provides a stable platform for continued growth and development.

For more detailed information and updates, please visit Rhythm Pharmaceuticals' Investor Relations website.

Explore the complete 8-K earnings release (here) from Rhythm Pharmaceuticals Inc for further details.

This article first appeared on GuruFocus.

Yahoo Finance AU
Secret ATO form that 'doubles your tax break' from July 1
There's a little-known hack to stack your tax break, Nicole Pedersen-McKinnon says.
Yahoo Finance AU
Tax time: 2 million Aussies face ATO punishment
It might be tempting in a cost-of-living crisis, but Aussies can face consequences for trying to get a bigger tax return.
Moneywise
Warren Buffett once shared how he could've turned $114 into $400K with his dead-simple signature investing style
It’s about America.
Simply Wall St.
UK Growth Companies With High Insider Ownership In June 2024
As global markets show signs of recovery, with indices like the FTSE 100 poised for gains amid easing monetary policies and robust economic indicators, the United Kingdom's financial landscape remains a focal point for investors. In such an environment, growth companies with high insider ownership can be particularly compelling, as they often signify a strong alignment between company management and shareholder interests.
Yahoo Finance AU
Centrelink, Tax, Superannuation: All the major law changes coming from July 1
Tax cuts, superannuation increases and Centrelink payment boosts are among the changes coming in the new financial year.
Simply Wall St.
Institutional investors may adopt severe steps after Woolworths Holdings Limited's (JSE:WHL) latest 9.2% drop adds to a year losses
Key Insights Given the large stake in the stock by institutions, Woolworths Holdings' stock price might be vulnerable...
Insider Monkey
The Best Cheap Cologne for Men That Smells Amazing
In this article, we will talk about The Best Cheap Cologne for Men That Smells Amazing. For our detailed discussion, go directly to the head to 15 Best Cheap Colognes for Men That Smell Amazing. Global Perfume Industry: The global perfume market was valued at $50.85 billion in 2022 and is anticipated to boost at […]
NCA NewsWire
ASX pares back losses as financials rally
The Australian share market has started the week in positive territory, as it extended its gains thanks to the big banks.
Simply Wall St.
An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 35% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£29.89 Hikma...
Bloomberg
GameStop Shares Surge as Gill’s Reddit Return Shows Huge Bet
(Bloomberg) -- GameStop Corp. shares surged after the Reddit account that drove the meme-stock mania of 2021 posted what appeared to be a $116 million position in the video-game retailer.Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Huge BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAMLO Protege Sheinbaum Becomes First
Simply Wall St.
Is SEEK Limited (ASX:SEK) Potentially Undervalued?
While SEEK Limited ( ASX:SEK ) might not have the largest market cap around , it received a lot of attention from a...
Yahoo Finance Video
Ford wants to make affordable EVs. How long could that take?
Ford (F) CEO Jim Farley hinted at the automaker's plans to roll out more affordable EVs in an exclusive interview with Yahoo Finance. RBC Capital Markets Global Autos Analyst Tom Narayan sits down with The Morning Brief to react to Ford's projected pathway to reach profitability on more affordable electric vehicles. "I think it has to be at the same price pretty much as an ICE [internal combustion engine] car, right? So you know, the average ICE cars though have gone up quite a bit. So they're almost like... $40,000 in the United States, an EV is probably more like $50,000 to $60,000," Narayan says to Yahoo Finance. "When you get the IRA credits, which are $7,500 off that, maybe the battery prices come down. If you can get them in that $30,000 to $40,000 range, I think they get more interesting. And you definitely have that push, right, to get the $20,000 to $30,000, EV that will come. It'll be a little difficult to get there." Narayan also comments on the consumer mentality behind range anxieties and concerns around EV charging infrastructure in the United States. Catch Yahoo Finance Executive Editor Brian Sozzi's full interview with Ford CEO and President Jim Farley. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
Simply Wall St.
JDE Peet's (AMS:JDEP) May Have Issues Allocating Its Capital
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Bloomberg
Modi Awaits Fate as Indian Markets Already Cheer Third Term Win
(Bloomberg) -- India will announce election results Tuesday, with investors already cheering a third term victory for Prime Minister Narendra Modi based on exit polls, pushing stocks to a record.Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Huge BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAMLO Protege Sheinbaum Becom
WWD
EXCLUSIVE: Shinola, Filson Parent Company Names New CEO, Chief Marketing Officer
Bedrock Manufacturing Company has announced several changes to its leadership team to strengthen its foundation in operating consumer brands.
Yahoo Finance Video
A 'two-lane' economy is weighing on the Fed: Strategist
The Institute for Supply Management's manufacturing Purchasing Managers' Index (PMI) fell to 48.7 in May from 49.2 in April, falling below analyst expectations. Saxo Chief Global Equity Strategist Peter Garnry joins Catalysts to explain what this print could signal for the Federal Reserve's next interest rate decision. "We are facing a world where China is pushing on an export string, and that's really pressuring manufacturing both in Europe and the US," Garnry explains. He believes that the harder China pushes on its export policy, the harder the US and Europe will push back. "In the short run, it could cause lower goods inflation in the global economy. But longer run, the goods inflation will be higher because it will force the US and Europe to be more protectionist [in its] trade policies and put up tariffs around their economies," he adds. As Wall Street eyes the Fed's next rate move, Garnry says the Fed is grappling with a "two-lane economy," where one part is sensitive to interest rates while the other part remains resilient. Garnry predicts a rate cut later in the year and adds that the US needs to get past the presidential election to see how the market pivots. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Yahoo Finance
Oil companies 'make up for lost time' as consolidation sweeps across industry
Last year, the energy industry spent $234 billion on M&A, the highest amount since 2012 when adjusted for inflation.
GOBankingRates
8 Ways Baby Boomers Become Poor in Retirement
As the baby boomer generation enters retirement, a growing number of them face unexpected financial challenges that threaten their retirement security. Try This: Retired But Want To Work? Try These 10...
Bloomberg
Global Banks Start Targeting a New Breed of Real Estate Risk
(Bloomberg) -- At some of the world’s biggest banks, loans to commercial real estate face new litmus tests that promise to shape the sector’s access to financing. Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Huge BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAMLO Protege Sheinbaum Becomes First Female President in Mex
South China Morning Post
Hong Kong stocks jump by most in 3 weeks as Alibaba, Tencent gain on economic data boost
Hong Kong stocks rose by the most in over three weeks after a private report showed the manufacturing sector in mainland China expanded more than expected last month, in contrast with an unexpected contraction in official data. The Hang Seng Index jumped 1.9 per cent to 18,415.14 at 3.10pm local time, the biggest advance since May 10. The Tech Index soared 2.4 per cent while the Shanghai Composite Index declined 0.3 per cent. All but nine out of the 82 index members gained. Tencent jumped 4.3 pe

ALL ORDS

AUD/USD

ASX 200

OIL

GOLD

Bitcoin AUD

CMC Crypto 200

Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges

Company Profile

Financial Performance and Strategic Milestones

Operational and Financial Outlook

Analysis of Financial Statements

Latest stories

Secret ATO form that 'doubles your tax break' from July 1

Tax time: 2 million Aussies face ATO punishment

Warren Buffett once shared how he could've turned $114 into $400K with his dead-simple signature investing style

UK Growth Companies With High Insider Ownership In June 2024

Centrelink, Tax, Superannuation: All the major law changes coming from July 1

Institutional investors may adopt severe steps after Woolworths Holdings Limited's (JSE:WHL) latest 9.2% drop adds to a year losses

The Best Cheap Cologne for Men That Smells Amazing

ASX pares back losses as financials rally

An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 35% Undervalued

GameStop Shares Surge as Gill’s Reddit Return Shows Huge Bet

Is SEEK Limited (ASX:SEK) Potentially Undervalued?

Ford wants to make affordable EVs. How long could that take?

JDE Peet's (AMS:JDEP) May Have Issues Allocating Its Capital

Modi Awaits Fate as Indian Markets Already Cheer Third Term Win

EXCLUSIVE: Shinola, Filson Parent Company Names New CEO, Chief Marketing Officer

A 'two-lane' economy is weighing on the Fed: Strategist

Oil companies 'make up for lost time' as consolidation sweeps across industry

8 Ways Baby Boomers Become Poor in Retirement

Global Banks Start Targeting a New Breed of Real Estate Risk

Hong Kong stocks jump by most in 3 weeks as Alibaba, Tencent gain on economic data boost